fish oil
Trade name: Omegavan
Animal productapprovedOrphan Drug FDA
Approved
Jul 13, 2016
Fish oil is oil derived from the tissues of oily fish. Fish oils contain the omega−3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), precursors of certain eicosanoids that are known to reduce inflammation in the body and improve hypertriglyceridemia. There has been a great deal of controversy in the 21st century about the role of fish oil in cardiovascular disease, with recent meta-analyses reaching different conclusions about its potential impact. — Wikipedia
Clinical trial activity
390 trials · 379 clinical orgs · 1 marketing orgs
Phase 1
33
Phase 2
109
Phase 3
58
Phase 4
30
Earliest trial started Nov 1, 1989 (NCT01353807)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
2000s
Indications
Studied for
- Abdominal Neoplasms · Phase 4
- Absorption · Phase 4
- Acute Lung Injury · Phase 2
- Adiposity · Phase 2
- Aggression · Phase 2/Phase 3
- Aging · Phase 3
- Alcoholism · Phase 1
- Allergy and Immunology · Phase 2/Phase 3
- Alzheimer Disease · Phase 3
- Anemia, Sickle Cell · Phase 2
- Anorexia Nervosa · Phase 2
- Antisocial Personality Disorder · Phase 2/Phase 3
- Anxiety · Phase 2/Phase 3
- Arrhythmias, Cardiac · Phase 4
- Arthritis, Rheumatoid · Phase 3
- Asthma · Phase 3
- Atherosclerosis · Phase 1
- Atrial Fibrillation · Phase 4
- Atrial Flutter · Phase 4
- Attention Deficit Disorder with Hyperactivity · Phase 3
- Bipolar Disorder · Phase 4
- Brain Concussion · Phase 1
- Breast Diseases · Phase 2
- Breast Neoplasms · Phase 4
- Bronchopulmonary Dysplasia · Phase 3
- Cachexia · Phase 4
- Cardiac Surgical Procedures · Phase 2/Phase 3
- Cardiomegaly · Phase 1
- Cardiopulmonary Bypass · Phase 2
- Cardiovascular Diseases · Phase 3
- Child Development · Phase 3
- Cholangitis, Sclerosing · Phase 1
- Cholestasis · Phase 3
- Chylomicrons · Phase 2
- Cognition Disorders · Phase 4
- Cognitive Dysfunction · Phase 4
- Colitis · Phase 2
- Colonic Neoplasms · Phase 4
- Colorectal Neoplasms · Phase 2
- Coronary Artery Bypass · Phase 2
- Coronary Artery Disease · Phase 4
- COVID-19 · Phase 2
- Critical Illness · Phase 4
- Crohn Disease · Phase 4
- Cystic Fibrosis · Phase 2
- Death, Sudden, Cardiac · Phase 1/Phase 2
- Dementia · Phase 1/Phase 2
- Depression · Phase 3
- Diabetes, Gestational · Phase 2
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 2 · Phase 2
- Diabetic Neuropathies · Early Phase 1
- Dietary Supplements · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 2
- Dyslipidemias · Phase 3
- Endometriosis · Phase 4
- Endothelial Cells · Phase 2
- Energy Transfer · Phase 4
- Enteral Nutrition · Phase 2/Phase 3
- Epilepsy · Phase 3
- Esophageal Atresia · Phase 2
- Esophageal Neoplasms · Phase 3
- Esophagitis · Phase 2
- Fatigue · Phase 2
- Fatty Acids · Phase 2/Phase 3
- Fatty Acids, Omega-3 · Phase 3
- Fatty Liver · Phase 3
- Feeding Behavior · Phase 2
- Fish Oils · Phase 2
- Gastrointestinal Absorption · Phase 4
- Gastrointestinal Diseases · Phase 2/Phase 3
- Gastroschisis · Phase 2
- General Surgery · Phase 4
- Genetic Diseases, X-Linked · Phase 2
- Gingivitis · Phase 2
- Health · Phase 4
- Healthy Volunteers · Phase 4
- Heart Disease Risk Factors · Phase 2
- Heart Failure · Phase 3
- Hematopoietic Stem Cell Transplantation · Phase 1
- HIV Infections · Phase 3
- Hypercholesterolemia · Phase 2
- Hyperlipidemias · Phase 4
- Hypertension · Phase 3
- Hypertension, Pregnancy-Induced · Phase 1
- Hypertriglyceridemia · Phase 2
- Infant, Premature, Diseases · Phase 2
- Inflammation · Phase 4
- Insulin Resistance · Phase 3
- Intensive Care Units · Phase 2
- Intestinal Atresia · Phase 2
- Intestinal Diseases · Phase 3
- Intestinal Neoplasms · Phase 4
- Kidney Diseases · Phase 3
- Kidney Failure, Chronic · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lipid Metabolism Disorders · Phase 1
- Live Birth · Phase 2
- Liver Cirrhosis · Phase 3
- Liver Diseases · Phase 4
- Lung Neoplasms · Phase 3
- Lupus Erythematosus, Systemic · Phase 2
- Macula Lutea · Phase 4
- Macular Degeneration · Phase 1
- Major Depressive Disorder · Phase 2/Phase 3
- Metabolic Syndrome · Phase 3
- Metabolism · Phase 2
- Mucositis · Phase 2
- Multiple Sclerosis · Phase 2/Phase 3
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Muscular Dystrophy, Duchenne · Phase 2
- Neonatology · Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 3
- Neurodevelopmental Disorders · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 3
- Obesity · Phase 4
- Obesity, Abdominal · Early Phase 1
- Obstetric Labor, Premature · Phase 2
- Overweight · Phase 3
- Oxidative Stress · Phase 2/Phase 3
- Pancreatic Neoplasms · Phase 4
- Pancreatitis · Phase 2
- Parenteral Nutrition · Phase 4
- Parkinson Disease · Phase 1
- Periodontitis · Phase 2
- Peripheral Arterial Disease · Phase 2
- Physiology · Phase 1
- Plaque, Atherosclerotic · Phase 1
- Polycystic Ovary Syndrome · Phase 4
- Pre-Eclampsia · Phase 1
- Pregnancy · Phase 3
- Pregnancy Complications · Phase 2
- Premature Birth · Phase 3
- Prostatic Neoplasms · Phase 2
- Protein Deficiency · Phase 4
- Proteomics · Phase 2
- Psychotic Disorders · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Quality of Life · Phase 4
- Radiotherapy · Phase 4
- Respiratory Distress Syndrome · Phase 2
- Retinitis Pigmentosa · Phase 2
- Retinopathy of Prematurity · Phase 2
- Risk · Phase 2
- Schizophrenia · Phase 4
- Sepsis · Phase 2
- Severe Acute Malnutrition · Phase 2
- Short Bowel Syndrome · Phase 2/Phase 3
- Smoking Cessation · Phase 2
- Stomach Neoplasms · Phase 4
- Surgical Procedures, Operative · Phase 2
- Tachycardia, Ventricular · Phase 1/Phase 2
- Thoracic Surgery · Phase 2
- Thrombosis · Early Phase 1
- Tobacco Use Disorder · Phase 3
- Vascular Surgical Procedures · Phase 2
- Weight Loss · Phase 4
Mechanism of action
- Unspecified targetOTHER
Supplement
- UnclearUnclear
Unclear unclear
Combination products
smoflipi
Approval history
- approvedJul 13, 2016
Chemistry & pharmacology
Loading structure…
SMILES
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O- Mol. weight
- 328.5 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFish oil ↗
- NCATSXGF7L72M0F ↗
- ChEMBLCHEMBL4297535 ↗
- ChEMBLCHEMBL3833369 ↗
- ChEMBLCHEMBL367149 ↗
Also known as
- docosahexaenoic acid
- docosahexaenoic acid
- docosahexaenoic acid
- docosahexaenoic acid
- efalex
- fish oil
- fish oil
- fish oil triglycerides
- omegavan
- omegaven
- omegaven
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06665464 | N/A | Nov 30, 2025 | Wageningen University |
| NCT07241377 | Phase 3 | Oct 27, 2025 | RDC Clinical Pty Ltd |
| NCT07086573 | N/A | Sep 22, 2025 | Nutricia, Utrecht University, Wageningen University |
| NCT06992726 | Phase 4 | Aug 1, 2025 | Capital Medical University |
| NCT06629103 | Phase 4 | Jan 31, 2025 | RDC Clinical Pty Ltd |
| NCT06758778 | N/A | Jan 3, 2025 | SICHUAN CREDIT PHARMACEUTICAL CO., LTD. |
| NCT06695910 | Phase 4 | Nov 6, 2024 | Institut de recherche clinique du littoral (IRCL), SCF Pharma |
| NCT06424860 | Phase 1 | Oct 1, 2024 | Heart and Stroke Foundation of Canada, University of Alberta |
| NCT06531460 | N/A | Jul 25, 2024 | Government of Mexico, Instituto Nacional de Enfermedades Respiratorias |
| NCT06877494 | Phase 2 | Jul 21, 2024 | Shanghai Eye Disease Prevention and Treatment Center |
| NCT06492694 | N/A | Jun 10, 2024 | doTERRA |
| NCT06659068 | N/A | May 16, 2024 | Universitas Sriwijaya |
| NCT06279793 | Phase 2 | Feb 15, 2024 | GCP-Service International Ltd. & Co. KG, Humboldt University, Johannes Gutenburg University, Julius-Maximilians University, Universitaetsklinikum Schleswig-Holstein, University of Augsburg, University of Bonn, University of Goettingen, University of Hamburg, University of Munster |
| NCT06233825 | N/A | Feb 1, 2024 | Queen's University, Belfast |
| NCT06074250 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2024 | Lotte & John Hecht Memorial Foundation, The Canadian College of Naturopathic Medicine, University of Toronto |
| NCT06005454 | N/A | Sep 1, 2023 | Cairo University |
| NCT05971147 | N/A | Aug 1, 2023 | Queen's University, Belfast |
| NCT05822141 | N/A | Jun 12, 2023 | Indiana University |
| NCT05869526 | N/A | May 1, 2023 | University of Glasgow |
| NCT05613803 | Phase 3 | Jan 31, 2023 | University of East Anglia |
Showing 20 of 390 trials
Page 1 / 20
Organizations
Research & Development (379)
379 organizations
Page 1 / 19